Sharon Harrison1,2, Julia Judd3, Sheray Chin2,4, Camille Ragin5,6. 1. Cancer Prevention and Control Program, Fox Chase Cancer Center, 333 Cottman Ave., Philadelphia, PA, 19111, USA. 2. African Caribbean Cancer Consortium, Philadelphia, PA, 19111, USA. 3. Department of Hematology/Oncology, Fox Chase Cancer Center, Temple University Hospital, 333 Cottman Ave., Philadelphia, PA, 19111, USA. 4. Department of Pathology (Division of Haematology & Oncology), Faculty of Medical Sciences, University of the West Indies, Mona, Jamaica. 5. Cancer Prevention and Control Program, Fox Chase Cancer Center, 333 Cottman Ave., Philadelphia, PA, 19111, USA. Camille.Ragin@fccc.edu. 6. African Caribbean Cancer Consortium, Philadelphia, PA, 19111, USA. Camille.Ragin@fccc.edu.
Abstract
PURPOSE OF REVIEW: Despite an overall reduction in lung cancer incidence and mortality rates worldwide, Blacks still have higher mortality rates compared to Whites. There are many factors that contribute to this difference. This review seeks to highlight racial disparities in treatment and the possible reasons for these disparities. RECENT FINDINGS: Factors attributing to racial disparities in lung cancer treatment include social determinants of health, differences in the administration of guideline-concordant therapy as well as molecular testing that is essential for most NSCLC patients. One way to circumvent disparities in lung cancer survivorship is to ensure equal representation of race in research at all levels that will provide insight on interventions that will address social determinants of health, differences in treatment patterns, molecular testing, and clinical trial involvement.
PURPOSE OF REVIEW: Despite an overall reduction in lung cancer incidence and mortality rates worldwide, Blacks still have higher mortality rates compared to Whites. There are many factors that contribute to this difference. This review seeks to highlight racial disparities in treatment and the possible reasons for these disparities. RECENT FINDINGS: Factors attributing to racial disparities in lung cancer treatment include social determinants of health, differences in the administration of guideline-concordant therapy as well as molecular testing that is essential for most NSCLC patients. One way to circumvent disparities in lung cancer survivorship is to ensure equal representation of race in research at all levels that will provide insight on interventions that will address social determinants of health, differences in treatment patterns, molecular testing, and clinical trial involvement.
Authors: Carol E DeSantis; Kimberly D Miller; Ann Goding Sauer; Ahmedin Jemal; Rebecca L Siegel Journal: CA Cancer J Clin Date: 2019-02-14 Impact factor: 508.702
Authors: David Ball; G Tao Mai; Shalini Vinod; Scott Babington; Jeremy Ruben; Tomas Kron; Brent Chesson; Alan Herschtal; Marijana Vanevski; Angela Rezo; Christine Elder; Marketa Skala; Andrew Wirth; Greg Wheeler; Adeline Lim; Mark Shaw; Penelope Schofield; Louis Irving; Benjamin Solomon Journal: Lancet Oncol Date: 2019-02-12 Impact factor: 41.316
Authors: Martin Reck; Delvys Rodríguez-Abreu; Andrew G Robinson; Rina Hui; Tibor Csőszi; Andrea Fülöp; Maya Gottfried; Nir Peled; Ali Tafreshi; Sinead Cuffe; Mary O'Brien; Suman Rao; Katsuyuki Hotta; Melanie A Leiby; Gregory M Lubiniecki; Yue Shentu; Reshma Rangwala; Julie R Brahmer Journal: N Engl J Med Date: 2016-10-08 Impact factor: 91.245
Authors: Luis Paz-Ares; Alexander Luft; David Vicente; Ali Tafreshi; Mahmut Gümüş; Julien Mazières; Barbara Hermes; Filiz Çay Şenler; Tibor Csőszi; Andrea Fülöp; Jerónimo Rodríguez-Cid; Jonathan Wilson; Shunichi Sugawara; Terufumi Kato; Ki Hyeong Lee; Ying Cheng; Silvia Novello; Balazs Halmos; Xiaodong Li; Gregory M Lubiniecki; Bilal Piperdi; Dariusz M Kowalski Journal: N Engl J Med Date: 2018-09-25 Impact factor: 91.245
Authors: Miranda B Lam; Katherine Raphael; Winta T Mehtsun; Jessica Phelan; E John Orav; Ashish K Jha; Jose F Figueroa Journal: JAMA Netw Open Date: 2020-12-01
Authors: Steven S Coughlin; Patricia Matthews-Juarez; Paul D Juarez; Courtnee E Melton; Mario King Journal: Cancer Med Date: 2014-09-14 Impact factor: 4.452
Authors: Julie A Lynch; Brygida Berse; Merry Rabb; Paul Mosquin; Rob Chew; Suzanne L West; Nicole Coomer; Daniel Becker; John Kautter Journal: BMC Cancer Date: 2018-03-20 Impact factor: 4.430